<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36690429</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A roadmap to ALS prevention: strategies and priorities.</ArticleTitle><Pagination><StartPage>399</StartPage><EndPage>402</EndPage><MedlinePgn>399-402</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2022-330473</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4241-5135</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA MBenatar@med.miami.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0001-8780-6637</Identifier><AffiliationInfo><Affiliation>Neurology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staats</LastName><ForeName>Kim A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0001-8392-7992</Identifier><AffiliationInfo><Affiliation>Staats Life Sciences Consulting, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Neurology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weisskopf</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4513-9834</Identifier><AffiliationInfo><Affiliation>Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbott</LastName><ForeName>Evelyn</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dave</LastName><ForeName>Kuldip D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>ALS Association, Washington, District of Columbia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thakur</LastName><ForeName>Neil M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>ALS Association, Washington, District of Columbia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AL-CHALABI/APR15/844-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-TALBOT/APR14/926-794</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS105479</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword></KeywordList><CoiStatement>Competing interests: MB reports grants from the National Institutes of Health (R01-NS105479) and the Muscular Dystrophy Association; as well as consulting fees from Alector, Annexon, Biogen, Denali, Novartis, Orphazyme, Sanofi and UniQure. The University of Miami has licensed intellectual property to Biogen to support design of the ATLAS study. SAG reports grants from National Institutes of Health, Centers for Disease Control and Prevention (CDC/ATSDR), and the ALS Association, as well as consulting fees from Structure Films. He is listed as inventor on patent held by University of Michigan for the treatment of ALS and reports the participation on a Data Safety Monitoring Board or Advisory Board for Watermark. KAS reports consulting fees from the ALS Association. ELF reports grants from the National Institutes of Health, Centers for Disease Control and Prevention (CDC/ATSDR), the Novo Nordisk Foundation, and the Juvenile Diabetes Research Foundation. She is named as inventor on a patent held by University of Michigan titled 'Methods For Treating Amyotrophic Lateral Sclerosis' for treating ALS using JAK/STAT inhibitors and reports multiple positions on Data Safety Monitoring Boards, Advisory Boards or or other boards, as well as multiple editorial positions. MW reports grants from the National Institutes of Health and the Centers for Disease Control and Prevention, as well as consulting fees from the Spaulding Rehabilitation. He additionally reports membership on a Data Safety Monitoring Board or Advisory Board for Biogen, a leadership role for the International Society for Environmental Epidemiology, and an editorial position with Springer. ET reports a position in the Pa Rare Disease Task Force. KDD reports the support of the preparation of this manuscript from the ALS Association and the ASTDR&#x2019;s National ALS Registry. NMT reports the support of the preparation of this manuscript from the ALS Association and the ASTDR&#x2019;s National ALS Registry. AA-C reports consultancies or advisory boards for Amylyx, Apellis, Biogen, Brainstorm, Cytokinetics, GenieUs, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Quralis and Wave Pharmaceuticals.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>23</Day><Hour>21</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36690429</ArticleId><ArticleId IdType="pmc">PMC10176353</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2022-330473</ArticleId><ArticleId IdType="pii">jnnp-2022-330473</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johnston CA, Stanton BR, Turner MR, et al. . Amyotrophic lateral sclerosis in an urban setting: a population based study of inner City London. J Neurol 2006;253:1642&#x2013;3. 10.1007/s00415-006-0195-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-006-0195-y</ArticleId><ArticleId IdType="pubmed">17219036</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Genge A, et al. . Trial of antisense oligonucleotide tofersen for SOD1 ALS. NEJM 2022. 10.1056/NEJMoa2204705</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, Ludolph AC, Huebers A. Disease-Modifying and symptomatic treatment of amyotrophic lateral sclerosis. Ther Adv Neurol Disord 2018;11:1756285617734734. 10.1177/1756285617734734</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285617734734</ArticleId><ArticleId IdType="pmc">PMC5784546</ArticleId><ArticleId IdType="pubmed">29399045</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, McHutchison C, et al. . Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain 2022;145:27&#x2013;44. 10.1093/brain/awab404</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab404</ArticleId><ArticleId IdType="pmc">PMC8967095</ArticleId><ArticleId IdType="pubmed">34677606</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology 2012;79:1732&#x2013;9. 10.1212/WNL.0b013e31826e9b1d</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31826e9b1d</ArticleId><ArticleId IdType="pmc">PMC3468777</ArticleId><ArticleId IdType="pubmed">23071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, et al. . Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol 2018;84:130&#x2013;9. 10.1002/ana.25276</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, et al. . Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:538&#x2013;48. 10.1080/21678421.2019.1646769</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. . Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 2020;383:109&#x2013;19. 10.1056/NEJMoa2003715</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Smith R, Pestronk A. Results of a phase 1, double-blind, placebo-controlled, dose-escalation study of the safety, tolerability, and pharmacokinetics of ISIS-333611 administered intrathecally to patients with familial ALS due to SOD1 gene mutations. American Academy of Neurology 2012.</Citation></Reference><Reference><Citation>Benatar M, Wuu J, Andersen P. Design of a phase 3, randomized, placebo-controlled trial of tofersen in clinically pre-symptomatic SOD1 mutation carriers: the ATLAS study. American Academy of Neurology Annual Meeting 2021:Virtual.</Citation></Reference><Reference><Citation>Al-Chalabi A, Calvo A, Chio A, et al. . Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 2014;13:1108&#x2013;13. 10.1016/S1474-4422(14)70219-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70219-4</ArticleId><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9:617&#x2013;28. 10.1038/nrneurol.2013.203</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Raymond J, Punjani R, et al. . Incidence of amyotrophic lateral sclerosis in the United States, 2014-2016. Amyotroph Lateral Scler Frontotemporal Degener 2022;23:378&#x2013;82. 10.1080/21678421.2021.2023190</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.2023190</ArticleId><ArticleId IdType="pubmed">35023792</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van der Spek RAA, Bakker MK, et al. . Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet 2021;53:1636&#x2013;48. 10.1038/s41588-021-00973-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Garton FC, Trabjerg BB, Wray NR, et al. . Cardiovascular disease, psychiatric diagnosis and sex differences in the multistep hypothesis of amyotrophic lateral sclerosis. Eur J Neurol 2021;28:421&#x2013;9. 10.1111/ene.14554</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14554</ArticleId><ArticleId IdType="pubmed">32978838</ArticleId></ArticleIdList></Reference><Reference><Citation>Min JL, Hemani G, Hannon E, et al. . Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. Nat Genet 2021;53:1311&#x2013;21. 10.1038/s41588-021-00923-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00923-x</ArticleId><ArticleId IdType="pmc">PMC7612069</ArticleId><ArticleId IdType="pubmed">34493871</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mazzini L, D'Alfonso S, et al. . The multistep hypothesis of ALS revisited: the role of genetic mutations. Neurology 2018;91:e635&#x2013;42. 10.1212/WNL.0000000000005996</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005996</ArticleId><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, Kapogiannis D, Huey ED, et al. . Ftd and ALS: a tale of two diseases. Curr Alzheimer Res 2011;8:273&#x2013;94. 10.2174/156720511795563700</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720511795563700</ArticleId><ArticleId IdType="pmc">PMC3801195</ArticleId><ArticleId IdType="pubmed">21222600</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve B, Bove J, Brannelly P, et al. . The longitudinal evaluation of familial frontotemporal dementia subjects protocol: framework and methodology. Alzheimers Dement 2020;16:22&#x2013;36. 10.1016/j.jalz.2019.06.4947</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.06.4947</ArticleId><ArticleId IdType="pmc">PMC6949411</ArticleId><ArticleId IdType="pubmed">31636026</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Granit V, Andersen PM, et al. . Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity. Brain 2022;145:3500&#x2013;8. 10.1093/brain/awac185</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac185</ArticleId><ArticleId IdType="pmc">PMC9586537</ArticleId><ArticleId IdType="pubmed">35594156</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Swash M. The onset of ALS? Clin Neurophysiol 2010;121:1709&#x2013;10. 10.1016/j.clinph.2010.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2010.03.002</ArticleId><ArticleId IdType="pubmed">20674486</ArticleId></ArticleIdList></Reference><Reference><Citation>Swash M, Ingram D. Preclinical and subclinical events in motor neuron disease. J Neurol Neurosurg Psychiatry 1988;51:165&#x2013;8. 10.1136/jnnp.51.2.165</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.51.2.165</ArticleId><ArticleId IdType="pmc">PMC1031524</ArticleId><ArticleId IdType="pubmed">3346681</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanby MF, Scott KM, Scotton W, et al. . The risk to relatives of patients with sporadic amyotrophic lateral sclerosis. Brain 2011;134:3454&#x2013;7. 10.1093/brain/awr248</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr248</ArticleId><ArticleId IdType="pmc">PMC3235555</ArticleId><ArticleId IdType="pubmed">21933809</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuquilin M, Wymer S, Wymer J. Increasing evidence for an association between amyotrophic lateral sclerosis and psychiatric disorders. JAMA Neurol 2017;74:1396&#x2013;8. 10.1001/jamaneurol.2017.1920</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1920</ArticleId><ArticleId IdType="pubmed">29049449</ArticleId></ArticleIdList></Reference><Reference><Citation>Horner RD, Kamins KG, Feussner JR, et al. . Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology 2003;61:742&#x2013;9. 10.1212/01.WNL.0000069922.32557.CA</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000069922.32557.CA</ArticleId><ArticleId IdType="pubmed">14504315</ArticleId></ArticleIdList></Reference><Reference><Citation>Haley RW. Excess incidence of ALS in young Gulf War veterans. Neurology 2003;61:750&#x2013;6. 10.1212/WNL.61.6.750</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.61.6.750</ArticleId><ArticleId IdType="pubmed">14504316</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard JD, Engel LS, Richardson DB, et al. . Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis survival. PLoS One 2017;12:e0185751. 10.1371/journal.pone.0185751</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0185751</ArticleId><ArticleId IdType="pmc">PMC5634564</ArticleId><ArticleId IdType="pubmed">29016608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagiraju HKR, &#x17d;ivkovi&#x107; S, VanCott AC, et al. . Amyotrophic lateral sclerosis among Veterans deployed in support of post-9/11 U.S. conflicts. Mil Med 2020;185:e501&#x2013;9. 10.1093/milmed/usz350</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/milmed/usz350</ArticleId><ArticleId IdType="pmc">PMC8921606</ArticleId><ArticleId IdType="pubmed">31642489</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Feldman EL. Voicing the need for amyotrophic lateral sclerosis environmental research. JAMA Neurol 2020;77:543&#x2013;4. 10.1001/jamaneurol.2020.0051</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0051</ArticleId><ArticleId IdType="pmc">PMC7977264</ArticleId><ArticleId IdType="pubmed">32119032</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Boss J, Godwin C, et al. . Associations of self-reported occupational exposures and settings to ALS: a case-control study. Int Arch Occup Environ Health 2022;95:1567&#x2013;86. 10.1007/s00420-022-01874-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00420-022-01874-4</ArticleId><ArticleId IdType="pmc">PMC9424174</ArticleId><ArticleId IdType="pubmed">35593931</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew A, Zhou J, Gui J, et al. . Pesticides applied to crops and amyotrophic lateral sclerosis risk in the U.S. Neurotoxicology 2021;87:128&#x2013;35. 10.1016/j.neuro.2021.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2021.09.004</ArticleId><ArticleId IdType="pubmed">34562505</ArticleId></ArticleIdList></Reference><Reference><Citation>Su F-C, Goutman SA, Chernyak S, et al. . Association of environmental toxins with amyotrophic lateral sclerosis. JAMA Neurol 2016;73:803&#x2013;11. 10.1001/jamaneurol.2016.0594</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.0594</ArticleId><ArticleId IdType="pmc">PMC5032145</ArticleId><ArticleId IdType="pubmed">27159543</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M-D, Little J, Gomes J, et al. . Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis. Neurotoxicology 2017;61:101&#x2013;30. 10.1016/j.neuro.2016.06.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2016.06.015</ArticleId><ArticleId IdType="pubmed">27377857</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian TH, Glascow N, Barry ADF, et al. . Physical exercise is a risk factor for amyotrophic lateral sclerosis: convergent evidence from Mendelian randomisation, transcriptomics and risk genotypes. EBioMedicine 2021;68:103397. 10.1016/j.ebiom.2021.103397</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103397</ArticleId><ArticleId IdType="pmc">PMC8170114</ArticleId><ArticleId IdType="pubmed">34051439</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer PS. Parkinsonism and motor neuron disorders: lessons from Western Pacific ALS/PDC. J Neurol Sci 2022;433:120021. 10.1016/j.jns.2021.120021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.120021</ArticleId><ArticleId IdType="pubmed">34635325</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaca MP, Hamburg NM, Creager MA. Contemporary medical management of peripheral artery disease. Circ Res 2021;128:1868&#x2013;84. 10.1161/CIRCRESAHA.121.318258</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.318258</ArticleId><ArticleId IdType="pubmed">34110910</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer RM, Mayer B, Kuncl RW, et al. . Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of Medicare prescription drugs. Amyotroph Lateral Scler Frontotemporal Degener 2020;21:235&#x2013;45. 10.1080/21678421.2019.1682613</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1682613</ArticleId><ArticleId IdType="pmc">PMC9930913</ArticleId><ArticleId IdType="pubmed">31684770</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui C, Sun J, McKay KA, et al. . Medication use and risk of amyotrophic lateral sclerosis-a systematic review. BMC Med 2022;20:251. 10.1186/s12916-022-02442-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02442-w</ArticleId><ArticleId IdType="pmc">PMC9354307</ArticleId><ArticleId IdType="pubmed">35927763</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, Vaughan T, Wicks P, et al. . How common are ALS plateaus and reversals? Neurology 2016;86:808&#x2013;12. 10.1212/WNL.0000000000002251</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002251</ArticleId><ArticleId IdType="pmc">PMC4793781</ArticleId><ArticleId IdType="pubmed">26658909</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison D, Mehta P, van Es MA, et al. . "ALS reversals": demographics, disease characteristics, treatments, and co-morbidities. Amyotroph Lateral Scler Frontotemporal Degener 2018;19:495&#x2013;9. 10.1080/21678421.2018.1457059</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1457059</ArticleId><ArticleId IdType="pubmed">29607695</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson M, Libert F, Doranz BJ, et al. . Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722&#x2013;5. 10.1038/382722a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/382722a0</ArticleId><ArticleId IdType="pubmed">8751444</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed H, Gurrola T, Berman R, et al. . Targeting CCR5 as a component of an HIV-1 therapeutic strategy. Front Immunol 2021;12:816515. 10.3389/fimmu.2021.816515</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.816515</ArticleId><ArticleId IdType="pmc">PMC8811197</ArticleId><ArticleId IdType="pubmed">35126374</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie-Martin S, Wootton RE, Budu-Aggrey A, et al. . Relationship between smoking and ALS: Mendelian randomisation interrogation of causality. J Neurol Neurosurg Psychiatry 2020;91:1312&#x2013;5. 10.1136/jnnp-2020-323316</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323316</ArticleId><ArticleId IdType="pubmed">32848012</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>